Rationale and Design for the Vascular Outcomes Study Endovascular or Surgical Limb Revascularization for Pe (VOYAGER PAD)

American Heart Journal

199, 83-91

DOI: 10.1016/j.ahj.2018.01.011

Citation Report

#	Article	IF	Citations
1	Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?. Thrombosis and Haemostasis, 2018, 118, S12-S22.	4.6	34
2	ACC/AHA Versus ESC Guidelines for Diagnosis and Management of Peripheral Artery Disease: JACC Guideline Comparison. Journal of the American College of Cardiology, 2018, 72, 2789-2801.	12.0	66
3	Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. Journal of the American College of Cardiology, 2018, 71, 2450-2467.	12.0	65
4	Medical Management of Stable Peripheral Artery Disease: The COMPASS Trial. Perspectives From a Vascular Standpoint. International Angiology, 2018, 37, 255-260.	1.8	2
5	Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. Journal of the American College of Cardiology, 2018, 72, 999-1011.	12.0	107
6	The Evolving Treatment of Peripheral Arterial Disease: Preventing Ischaemic Events in the Post-COMPASS Era. Cardiovascular Research, 2019, 115, e121-e124.	13.5	3
7	Practice Patterns of Dual Antiplatelet Therapy After Lower Extremity Endovascular Interventions. Vascular Medicine, 2019, 24, 528-535.	2.3	9
8	Rivaroxaban Plus Aspirin for Cardiovascular Protection: Rationale for the Vascular Dose and Dual Pathway Inhibition. Thrombosis Research, 2019, 184, 44-49.	2.9	9
9	Dual Antiplatelet Therapy After Endovascular Revascularization of Infrainguinal Arteries. Vascular Medicine, 2019, 24, 536-538.	2.3	3
10	Rivaroxaban and Aspirin in Peripheral Vascular Disease: A Review of Implementation Strategies and Management of Common Clinical Scenarios. Current Cardiology Reports, 2019, 21, 1-9.	4.5	21
11	The Continuous Challenge of Antithrombotic Strategies in Diabetes: Focus on Direct Oral Anticoagulants. Acta Diabetologica, 2019, 56, 1247-1258.	3.8	7
12	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	3.4	1,544
13	Acute Limb Ischemia in Peripheral Artery Disease. Circulation, 2019, 140, 556-565.	24.6	133
14	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	3.2	1,478
15	Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?. Circulation, 2019, 140, 1342-1351.	24.6	45
16	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit – ein Überblick über aktuelle Evidenz, Praxis und Ausblick. Deutsche Medizinische Wochenschrift, 2019, 144, 683-689.	0.3	1
17	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation, 2019, 139, 2170-2185.	24.6	93
18	Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next. Vascular and Endovascular Surgery, 2019, 53, 325-336.	0.9	3

#	Article	IF	Citations
19	8. Jahrestagung der Vereinigung der interdisziplinären Gefäßmediziner Süddeutschlands (VIGS). Gefasschirurgie, 2019, 24, 176-181.	0.4	0
20	Antithrombotics in Stable Peripheral Artery Disease. Vascular Medicine, 2019, 24, 132-140.	2.3	16
21	Defining the Role of Open and Endovascular Therapy in Complex PAD Patients. JACC: Cardiovascular Interventions, 2019, 12, 2550-2552.	5.0	1
22	COMPASS for Vascular Surgeons: Practical Considerations. Current Opinion in Cardiology, 2019, 34, 178.	2.2	8
23	The Year 2018 in Cardiology: Aorta and Peripheral Circulation. European Heart Journal, 2019, 40, 872-879.	14.7	7
24	Prevention of Atherothrombotic Events in Patients With Diabetes Mellitus: From Antithrombotic Therapies to New-Generation Glucose-Lowering Drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	62.4	102
25	Coronary Artery Disease and Restenosis After Peripheral Endovascular Intervention Are Predictors of Poor Outcome in Peripheral Arterial Disease. Acta Cardiologica, 2020, 75, 649-656.	1.5	9
26	Pathologic Disparities Between Peripheral Artery Disease and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1982-1989.	7.9	133
27	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2
28	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	24.6	101
29	Clinical Significance of Thrombin Blockade With Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients. Rational Pharmacotherapy in Cardiology, 2020, 16, 99-107.	0.6	0
30	Reply. Journal of Vascular Surgery, 2020, 71, 1818-1819.	3.4	0
31	From the Masters: A Sea-Change for TransAtlantic Inter-Society Consensus (TASC). Vascular Medicine, 2020, 25, 103-105.	2.3	2
32	Rivaroxaban in Peripheral Artery Disease After Revascularization. New England Journal of Medicine, 2020, 382, 1994-2004.	76.6	1,000
33	Clinical Safety of Low-Dose Anticoagulation With Fondaparinux in Patients Undergoing Peripheral Endovascular Treatment Due to Critical Limb-Threatening Ischaemia – A Pilot Study. Acta Cardiologica, 2021, 76, 365-372.	1.5	1
34	Diabetes Mellitus: An Important Risk Factor for Peripheral Vascular Disease. Expert Review of Cardiovascular Therapy, 2020, 18, 131-137.	2.7	23
35	Dual Pathway Inhibition for Vascular Protection in Patients With Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis, 2020, 120, 1147-1158.	4.6	32
36	The Pathobiology of Acute Limb Ischemic Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. JACC: Cardiovascular Interventions, 2020, 13, 428-430.	5.0	0

#	Article	IF	Citations
37	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Current Cardiology Reports, 2020, 22, 1-18.	4.5	3
38	The Fate of Life and Limb After Peripheral Artery Revascularization. Journal of the American College of Cardiology, 2020, 75, 509-511.	12.0	1
39	The Voyager PAD Trial – New Path for Post-Revascularisation PAD Patients. European Journal of Vascular and Endovascular Surgery, 2020, 59, 699-700.	3.2	8
40	Impact of High On-Treatment Platelet Reactivity After Angioplasty in Patients With Peripheral Arterial Disease. Platelets, 2021, 32, 391-397.	3.8	15
41	The Role of Rivaroxaban for Patients With Atherosclerotic Vascular Disease in the Modern Era. Catheterization and Cardiovascular Interventions, 2021, 97, 1221-1229.	2.2	1
42	Chronic Mesenteric Ischemia: Clinical Practice Guidelines From the Society for Vascular Surgery. Journal of Vascular Surgery, 2021, 73, 87S-115S.	3.4	142
43	Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug-Drug Interaction Potential. Journal of Clinical Pharmacology, 2021, 61, 656-665.	2.4	33
44	A Case of Occluded Femoropopliteal Saphenous Vein Bypass With Threatening Limb Ischemia Treated With Endovascular Stent Graft Relining. Journal of Vascular Surgery Cases and Innovative Techniques, 2021, 7, 74-77.	0.9	1
45	Methods of Decreasing the Risk of Repeat Interventions in Patients After Arterial Revascularization. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 169-175.	0.2	0
46	Effects of Constraint Between Filaments on the Radial Compression Properties of Poly (l-Lactic Acid) Self-Expandable Braided Stents. Polymer Testing, 2021, 93, 106963.	6.2	12
47	Are There Alternatives to Dual Antiplatelet Therapy After Stenting of Peripheral Arteries?. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 22-27.	0.2	1
48	Medical Therapy for Cardiovascular and Limb-Related Risk Reduction in Critical Limb Ischemia. Vascular Medicine, 2021, 26, 210-224.	2.3	8
49	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Combined With Antiplatelet Drugs for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vascular, 2022, 30, 97-104.	1.1	2
50	Preoperative Stress Test and Postoperative MI in Patients Requiring Lower Extremity Bypass for Critical Limb Ischemia. Annals of Vascular Surgery, 2021, 72, 529-534.	1.8	3
51	Do We Have a Unified Consensus on Antithrombotic Management of PAD?. International Angiology, 2021, 40, 229-239.	1.8	1
52	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Gefasschirurgie, 2021, 26, 415-428.	0.4	1
53	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Geriatrie Up2date, 2021, 3, 195-205.	0.1	0
54	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. Journal of the American College of Cardiology, 2021, 78, 317-326.	12.0	50

#	Article	IF	Citations
55	Wider Lens, Sharper Focus. Journal of the American College of Cardiology, 2021, 78, 327-329.	12.0	0
56	Latin American Consensus on Management of Residual Cardiometabolic Risk. A Consensus Paper Prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2022, 92, 99-112.	0.2	15
57	Antithrombotische Therapie Bei Diabetes Mellitus. Diabetologe, 2021, 17, 825-833.	0.2	0
58	A Study of the Radial and Bending Performance for Poly (L-Lactic Acid) Braided Stents With Innovative Runners. Polymers for Advanced Technologies, 2021, 32, 4690-4699.	4.0	9
59	Antithrombotic Therapy in Patients With Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	5.9	17
60	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	24.6	48
61	Exploring the NT-proBNP Expression in Premature Infants With Patent Ductus Arteriosus (PDA) by Echocardiography. Pakistan Journal of Medical Sciences, 2021, 37, 1615-1619.	1.5	2
62	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. Journal of the American College of Cardiology, 2021, 78, 757-759.	12.0	11
63	Low-Dose Rivaroxaban Plus Aspirin in Older Patients With Peripheral Artery Disease Undergoing Acute Limb Revascularization: Insights From the VOYAGER PAD Trial. European Heart Journal, 2021, 42, 4040-4048.	14.7	23
64	Low-Dose Rivaroxaban and Aspirin Among Patients With Peripheral Artery Disease: A Meta-Analysis of the COMPASS and VOYAGER Trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	6.1	38
65	ESVM Guideline on Peripheral Arterial Disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-79.	2.7	192
66	5 Conservative Treatment for PAD – Risk Factor Management. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-12.	2.7	21
67	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2020, 07, 291-301.	0.0	1
68	Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом как оптимизировать прогноз?. Meditsinskiy Sovet, 2018, 0, 32-38.	0.4	5
69	Incidence and Predictors of Stent Thrombosis After Endovascular Revascularisation of the Superficial Femoral Artery. EuroIntervention, 2019, 15, e1107-e1114.	4.9	25
70	A Systematic Review and Meta-Analysis on the Efficacy and Safety of Direct Oral Anticoagulants in Patients With Peripheral Artery Disease. Annals of Vascular Surgery, 2022, 80, 1-11.	1.8	11
71	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 144, 1831-1841.	24.6	44
72	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	12.0	32

#	Article	IF	Citations
73	Renovascular Disease and Mesenteric Vascular Disease. Cardiology Clinics, 2021, 39, 527-537.	1.4	2
74	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Current Pharmaceutical Design, 2020, 26, 5953-5968.	3.4	5
75	Prevention of Peripheral Arterial Disease. Contemporary Cardiology, 2021, .	0.0	0
76	Concerning New Standards of Treatment of the Peripheral Arteries Diseases on Background of Modern Recommendations and Data of Clinical Investigations, Taking Into Account a Significance of Prophylaxis of Unfavorable Events With the Extremity and Cardio-VA. The Ukrainian Journal of Clinical Surgery, 2020, 87, 102-104.	0.1	0
77	Risk Factors and Pharmacological Therapy in Patients With Vascular Disease. Vascular Surgery, 2022, .	0.6	0
78	Clinical Profile and Outcomes of Isolated Femoropopliteal Interventions in Chronic Limb Threatening Ischaemia in India. Indian Journal of Surgery, 2023, 85, 168-176.	0.4	0
79	Importance of the Results of VOYAGER PAD Trial for Clinical Practice. , 2021, .		0
80	Dual Pathway of Inhibition and Vascular Protection in Patients With Atherosclerotic Disease. , 2021, .		0
81	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. European Journal of Vascular and Endovascular Surgery, 2022, 63, 285-294.	3.2	22
82	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
83	Practical Importance of COMPASS Trial Results for Vascular Surgeons. , 2020, .		0
84	Prevalence of VOYAGER PAD Trial Exclusion Criteria in Unselected Patients Undergoing Lower Limb Revascularization. International Angiology, 2022, 41, 56-62.	1.8	5
85	Improvement in Walking Impairment Following Surgical and Endovascular Revascularization: Insights From VOYAGER PAD. Vascular Medicine, 2022, 27, 343-349.	2.3	9
86	Antithrombotische Therapie Bei Diabetes Mellitus. Die Kardiologie, 2022, 16, 253-262.	1.4	0
87	Atherosclerotic Plaque Composition and Specific Endovascular Considerations in the End Stage Renal Disease Patients: A Narrative Review. Cardiovascular Diagnosis and Therapy, 2023, 13, 13346-13146.	2.1	3
88	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580-e2215580.	10.2	19
89	Endothelial Cell Dysfunction: Implications for the Pathogenesis of Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 1054576.	3.2	51
90	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions With the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. International Journal of Molecular Sciences, 2022, 23, 14914.	5.9	35

#	Article	IF	Citations
91	Rivaroxaban in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Bypass Surgery With Venous and Prosthetic Conduits. Journal of Vascular Surgery, 2023, 77, 1107-1118.e2.	3.4	21
92	Markers of Coagulation and Inflammation and Adverse Events in Patients With Active Cancer and Atherosclerosis: Common Features and Differences. Atherothrombosis, 2023, 12, 64-78.	0.5	6
93	Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison With the Voyager Pad Endovascular Cohort. Journal of Cardiovascular Development and Disease, 2023, 10, 115.	2.9	2
94	A Framework for Perioperative Care for Lower Extremity Vascular Bypasses: A Consensus Statement by the Enhanced Recovery After Surgery (ERAS®) Society and Society for Vascular Surgery. Journal of Vascular Surgery, 2023, 77, 1295-1315.	3.4	50
95	Optimal Medical Management in Patients Undergoing Peripheral Vascular Interventions for Chronic Limb-Threatening Ischemia Is Associated With Improved Outcomes. Journal of Vascular Surgery, 2023, 78, 490-497.	3.4	10
96	A Two-Species Finite Volume Scalar Model for Modeling the Diffusion of Poly(Lactic-Co-Glycolic Acid) Into a Coronary Arterial Wall From a Single Half-Embedded Drug Eluting Stent Strut. Biophysica, 2023, 3, 385-408.	1.8	3
97	Peripheral Artery Disease: Update on Etiology, Pathophysiology, Diagnosis and Treatment. Medicina Clínica, 2023, 161, 344-350.	1.2	71
98	Rag1 Deficiency Impairs Arteriogenesis in Mice. International Journal of Molecular Sciences, 2023, 24, 12839.	5.9	6
99	Assessment of Atherectomy Treatment for Thromboangiitis Obliterans: A Single Center Experience. Catheterization and Cardiovascular Interventions, 2023, 102, 713-720.	2.2	4
100	Peripheral Artery Disease: Update on Etiology, Pathophysiology, Diagnosis and Treatment. Medicina Clínica (English Edition), 2023, 161, 344-350.	0.2	1
101	Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation, 2023, 148, 1919-1928.	24.6	22
102	Methods, Design, and Initial Results of an Angiographic Core Lab From VOYAGER-PAD. Vascular Medicine, 2024, 29, 143-152.	2.3	0
103	The Paradox of Direct-Acting Anticoagulants in Peripheral Arterial Disease in Spain. Angiologia, 2024, .	0.1	0
104	Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association, 2024, 13, e032782.	5.8	11
105	Rationale and Design for the Randomized Placebo-Controlled Double-Blind Trial Studying the Effect of Single Antiplatelet Therapy (Clopidogrel) Versus Dual Antiplatelet Therapy (Clopidogrel/Acetylsalicylic Acid) on the Occurrence of Atherothrombotic Events Following Lower Extremity Peripheral Transluminal Angioplasty (CLEAR-PATH). American Heart Journal, 2024, 273, 121-129.	3.3	5
106	Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis. Journal of the American College of Cardiology, 2024, 83, 1627-1636.	12.0	12
107	Dual Antithrombotic Therapy Versus Anticoagulant Monotherapy for Major Adverse Limb Events in Patients With Concomitant Lower Extremity Arterial Disease and Atrial Fibrillation: A Propensity Score Weighted Analysis. European Journal of Vascular and Endovascular Surgery, 2024, 68, 498-507.	3.2	5
108	Assessing the Suitability of CHA2DS2-VASc for Predicting Adverse Limb Events and Cardiovascular Outcomes in Peripheral Artery Disease Patients With Percutaneous Transluminal Angioplasty: A Retrospective Cohort Study. Biomedicines, 2024, 12, 1374.	4.9	3

#	Article	IF	Citations
109	Показатели гемостаза у пациентов с артериальной гипертензией, мультифокальным атеросклерозом и факторами риска. Klinicist, 2024, 18, 49-58.	0.6	1
110	Effect of Peripheral Interventions in Patients With Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses From the XATOA Registry. European Journal of Vascular and Endovascular Surgery, 2024, 0, 784-795.	3.2	3
111	Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. Journal of the American College of Cardiology, 2024, 84, 801-811.	12.0	12
112	A Comparison Between Culprit Versus Complete Revascularization in Diabetic Patients With Acute Myocardial Infarction. Clinical Cardiology, 2024, 47, e70046.	3.1	1
113	Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. Journal of Vascular Surgery, 2025, 82, 303-326.e11.	3.4	28
114	Подходы к первичной и вторичной профилактике церебральных осложнений у пациентов с артериальной гипертензией и мультифокальным атеросклерозом. Meditsinskiy Sovet, 2025, 0, 124-132.	0.4	0
115	Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association, 2025, 14, e039752.	5.8	2
116	Effect of Rivaroxaban on DNA Damage in an Ischemia-Reperfusion Model: Evaluation of 8-OHdG Levels. Experimental and Therapeutic Medicine, 2026, 31, 1-7.	2.4	1
117	Influence of Malignant Neoplasms on Limb Prognosis in Patients With Peripheral Arterial Disease: A Real World Analysis Based on a Nationwide Database. European Journal of Vascular and Endovascular Surgery, 2026, 72, 582-588.	3.2	2
118	Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions, 2026, 19, e015229.	6.2	1
119	Secondary Prevention of Ishemic Stroke. Use of a Combination of Acetylsalicylic Acid With Low Doses of Rivaraxoban in Individuals With Multifocal Atherosclerosis. Medical Alphabet, 2026, .	0.3	0